VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient trader. VKTX is still in a bearish downswing (price below S1 support, negative/expanding MACD), and insider selling is accelerating (+206.5% last month). While options positioning is bullish (very low put/call ratios) and the GLP-1 obesity pipeline provides upside catalysts into 2026, the current tape suggests you’re more likely early on a falling knife than catching a clean reversal. I would HOLD rather than chase a bounce here.
Trend/momentum: Bearish short-term. The MACD histogram is negative (-0.274) and expanding lower, signaling downside momentum is still building. RSI(6) at 22.7 is oversold (bounce risk is rising), but oversold alone isn’t a confirmation of reversal.
Key levels: Price 29.11 is below S1 (29.671), meaning prior support just broke; next downside reference is S2 (28.247). Reclaiming ~29.67 and especially the pivot (31.98) would be the first signs the selloff is stabilizing. Upside resistance sits near 34.28 (R1).
Moving averages: Converging MAs suggest the stock may be entering a basing phase, but momentum indicators still favor sellers.
Intellectia Proprietary Trading Signals:
Pipeline/news flow remains supportive: VK2735 obesity/weight-loss program is in Phase 3 and repeatedly framed as a potential competitive entrant vs. leaders (e.g., Lilly). Company has >$700M cash cited in news, supporting continued development. Next scheduled catalyst: QDEC 2025 earnings on 2026-02-11 after hours (can move the stock on commentary/updates even pre-revenue).
and MACD is deteriorating, increasing the chance of continuation toward S2 (~28.25). Pre-revenue biotech profile means moves are highly headline-driven and the next earnings date can introduce downside if burn/guidance disappoints.
Latest quarter: 2025/Q3. Revenue remains effectively zero (no commercial ramp yet). Losses widened materially: net income -$90.8M (more negative YoY by the provided metric) and EPS -0.81 (more negative YoY), indicating higher spend/burn consistent with advancing late-stage trials rather than operating leverage.
No analyst rating/price target change data was provided, so a verified trend in upgrades/downgrades or target revisions can’t be concluded from this dataset. Street-style bull case would center on Phase 3 obesity upside and cash runway; bear case would focus on continued cash burn, trial/execution risk, and the stock’s current bearish technical setup.
